Skip to content

A single-center, prospective, open label randomized clinical trial to evaluate the efficacy and safety of transcatheter arterial embolization using ‘Nexsphere-F’ in patients with adhesive capsulitis of the shoulder joint refractory to conservative treatment.

A single-center, prospective, open label randomized clinical trial to evaluate the efficacy and safety of transcatheter arterial embolization using ‘Nexsphere-F’ in patients with adhesive capsulitis of the shoulder joint refractory to conservative treatment.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0010608
Enrollment
44
Registered
2025-06-09
Start date
2025-09-18
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Procedure/Surgery : Transcatheter embolization is performed. Transcatheter embolization is performed by approaching the radial artery and performing angiography on the painful area. After confirming a

Sponsors

Chung-Ang Univerisity Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: ? Patients who have voluntarily signed a written informed consent form after receiving an explanation of the purpose, methods, and potential effects of the clinical trial ? Patients aged between 19 and 85 years ? Patients with pain persisting for more than 3 months in the affected area and with a history of receiving physical therapy, analgesics/anti-inflammatory medications, or local injection treatments ? Patients with a measured shoulder joint range of motion (ROM) of less than 90 degrees ? Patients who agree not to receive any conservative treatment other than those permitted in this clinical trial (physical therapy, medication [NSAIDs, opioid analgesics, acetaminophen], intra-articular injections such as hyaluronic acid) ? Patients who are willing to comply with the treatment and procedures of the clinical trial and participate in all follow-up evaluations through hospital visits or telephone surveys

Exclusion criteria

Exclusion criteria: ? Patients with a history of surgery on the shoulder joint targeted for the clinical trial prior to screening ? Patients suspected of having a full-thickness rotator cuff tear ? Patients with bleeding disorders or coagulopathies (e.g., idiopathic thrombocytopenic purpura, hemophilia, disseminated intravascular coagulation) ? Patients with advanced atherosclerosis or vasospasm in the arm vessels, or those expected to have such conditions ? Patients with a known hypersensitivity to gelatin ? Patients with a known hypersensitivity to contrast media ? Patients who are pregnant or breastfeeding ? Patients with a localized infection at the pain site ? Patients deemed inappropriate for participation by the investigator due to ethical concerns or potential impact on the clinical trial results

Design outcomes

Primary

MeasureTime frame
VAS(Visual Analog Scale) score

Secondary

MeasureTime frame
Visual Analog Scale (VAS) scores at early follow-up;Shoulder joint range of motion (ROM);American Shoulder and Elbow Surgeons (ASES) score;Single Assessment Numeric Evaluation (SANE) score;Patient satisfaction with treatment;Structural changes of the shoulder joint assessed by magnetic resonance imaging (MRI)

Countries

Korea, Republic of

Contacts

Public ContactWoosun Choi

Chung-Ang Univerisity Hospital

radiochoi527@gmail.com+82-2-6299-2681

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026